BioLine RX Ltd. ADR | Balance Sheet

Fiscal year is January-December. All values ILS Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
63,233.00
134,873.00
185,459.10
137,100.50
171,787.70
112,666.70
Total Accounts Receivable
1,249.00
1,000.00
1,132.30
858.20
2,034.40
5,003.50
Other Current Assets
896.00
859.00
891.10
981.40
1,065.80
1,823.50
Total Current Assets
65,378.00
136,732.00
187,482.50
138,940.10
174,887.80
119,493.80
Net Property, Plant & Equipment
2,471.00
2,804.00
11,319.10
10,025.70
8,696.50
8,321.70
Total Investments and Advances
573.00
644.00
-
-
3,471.70
-
Intangible Assets
878.00
457.00
591.40
696.60
24,381.40
82,103.90
Other Assets
169.00
190.00
225.70
200.10
211.80
209.30
Total Assets
69,469.00
140,827.00
199,618.60
149,862.60
211,649.10
210,128.70
ST Debt & Current Portion LT Debt
-
-
361.90
357.90
322.90
Accounts Payable
7,945.00
-
7,431.90
9,968.00
19,149.60
Other Current Liabilities
2,499.00
11,300.00
4,424.10
3,764.00
3,863.90
Total Current Liabilities
10,444.00
11,300.00
12,217.90
14,089.90
23,336.40
Long-Term Debt
-
-
1,338.50
962.20
545.00
Provision for Risks & Charges
152.00
-
-
-
-
Other Liabilities
18,187.00
5,833.00
809.30
3.90
4,183.30
Total Liabilities
28,783.00
17,133.00
14,365.80
15,055.90
28,064.80
Common Equity (Total)
40,686.00
123,694.00
185,252.90
134,806.70
183,584.30
Total Shareholders' Equity
40,686.00
123,694.00
185,252.90
134,806.70
183,584.30
Total Equity
40,686.00
123,694.00
185,252.90
134,806.70
183,584.30
Liabilities & Shareholders' Equity
69,469.00
140,827.00
199,618.60
149,862.60
211,649.10

About BioLine RX

View Profile
Address
Modi'in Technology Park
Modi'in TA 7177871
Israel
Employees -
Website http://www.biolinerx.com
Updated 07/08/2019
BioLineRx Ltd. is a clinical-stage biopharmaceutical company, which includes indentifying, in-licensing, and developing therapeutic candidates. Its in-licenses novel compounds, primarily from academic institutions and biotech companies based in Israel, and develops them through pre-clinical and clinical stages, and then partners with pharmaceutical companies clinical development and commercialization. The company was founded in April 2003 and is headquartered in Modi'in, Israel.